These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 35252898)

  • 1. An Observational Study on Treatment Outcomes in Patients With Stage III NSCLC in Taiwan: The KINDLE Study.
    Su PL; Chang GC; Hsiao SH; Hsia TC; Lin MC; Lin MH; Shih JY; Yang CT; Yang SH; Chen YM
    JTO Clin Res Rep; 2022 Mar; 3(3):100292. PubMed ID: 35252898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world global data on targeting epidermal growth factor receptor mutations in stage III non-small-cell lung cancer: the results of the KINDLE study.
    Jazieh AR; Onal HC; Tan DS; Soo RA; Prabhash K; Kumar A; Huggenberger R; Cho BC
    Ther Adv Med Oncol; 2022; 14():17588359221122720. PubMed ID: 36119641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved survival in patients with unresectable stage III EGFR-mutant adenocarcinoma with upfront EGFR-tyrosine kinase inhibitors.
    Wang SY; Lai CH; Chen CW; Yang SC; Chang CC; Lin CY; Yen YT; Tseng YL; Su PL; Lin CC; Su WC
    Thorac Cancer; 2022 Jan; 13(2):182-189. PubMed ID: 34799993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world treatment patterns and clinical outcomes in patients with stage III non-small cell lung cancer: results of KINDLE-Egypt cohort.
    Aboelhassan R; Sobeih ME; El-Din MA; Ghali RR; El-Din IS; Khorshid O; Mokhtar M; Rabea AM; Belal A; Azim HA; Abdullah M; Elnahas T; Tawfik H; Abdelwahab S; Elsaid AA; Hashem T; Mancy M; Farag H
    Ther Adv Med Oncol; 2023; 15():17588359231212182. PubMed ID: 38028146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world treatment patterns and clinical outcomes in patients with stage III NSCLC in Korea: The KINDLE study.
    Lee J; Ahn HK; Kim SW; Han JY; Lee SS; Park HS; Lee HW; Kim JH; Cho E; Huggenberger R; Cho BC
    Cancer Med; 2024 Apr; 13(7):e7174. PubMed ID: 38622869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study.
    Schuette W; Schirmacher P; Eberhardt WEE; Dietel M; Zirrgiebel U; Muehlenhoff L; Thomas M
    BMC Cancer; 2018 Feb; 18(1):135. PubMed ID: 29402243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of medically inoperable and tyrosine kinase inhibitor-naïve early-stage lung adenocarcinoma with epidermal growth factor receptor mutations: a retrospective multi-institutional analysis.
    Sun Y; Wu M; Zhou M; Luo X; Guo Y; Bai H; Zhang Z; Tian W; Wang X; Bai Y; Zhu X; Pan H; Deng Y; Hu H; Xia J; Hao X; Han L; Wei M; Liu Y; Zeng M
    BMC Cancer; 2020 Jul; 20(1):646. PubMed ID: 32660443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-line treatment with irreversible tyrosine kinase inhibitors associated with longer OS in EGFR mutation-positive non-small cell lung cancer.
    Su PL; Chen CW; Wu YL; Lin CC; Su WC
    Thorac Cancer; 2021 Feb; 12(3):287-296. PubMed ID: 33336895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.
    Lee VH; Chan WW; Lee EY; Choy TS; Ho PP; Leung DK; Lam KO; Kwong DL; Leung TW; Khong PL
    Am J Clin Oncol; 2016 Aug; 39(4):355-62. PubMed ID: 24710123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy.
    Aredo JV; Mambetsariev I; Hellyer JA; Amini A; Neal JW; Padda SK; McCoach CE; Riess JW; Cabebe EC; Naidoo J; Abuali T; Salgia R; Loo BW; Diehn M; Han SS; Wakelee HA
    J Thorac Oncol; 2021 Jun; 16(6):1030-1041. PubMed ID: 33588109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer.
    Zhai H; Zhong W; Yang X; Wu YL
    Transl Lung Cancer Res; 2015 Feb; 4(1):82-93. PubMed ID: 25806348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR-TKI plus bevacizumab versus EGFR-TKI monotherapy for patients with EGFR mutation-positive advanced non-small cell lung cancer-A propensity score matching analysis.
    Tsai JS; Su PL; Yang SC; Chang CC; Lin CY; Yen YT; Tseng YL; Lai WW; Lin CC; Su WC
    J Formos Med Assoc; 2021 Sep; 120(9):1729-1739. PubMed ID: 33865672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world clinical practice and outcomes in treating stage III non-small cell lung cancer: KINDLE-Asia subset.
    Prabhash K; Tan DSW; Soo RA; Sitthideatphaiboon P; Chen YM; Voon PJ; Syahruddin E; Chu S; Huggenberger R; Cho BC
    Front Oncol; 2023; 13():1117348. PubMed ID: 37051534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.
    Buttigliero C; Shepherd FA; Barlesi F; Schwartz B; Orlov S; Favaretto AG; Santoro A; Hirsh V; Ramlau R; Blackler AR; Roder J; Spigel D; Novello S; Akerley W; Scagliotti GV
    Oncologist; 2019 Jun; 24(6):e251-e259. PubMed ID: 30139835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world treatment patterns and clinical outcomes in
    Bi N; Xu K; Ge H; Chen M; E M; Zhang L; Cao J; Zhang X; Ding X; Xia B; Zhao L; Han L; Li J; Hu C; Wang L
    J Natl Cancer Cent; 2023 Mar; 3(1):65-71. PubMed ID: 39036309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low Body Mass Index Is an Independent Prognostic Factor in Patients With Non-Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.
    Minami S; Ihara S; Nishimatsu K; Komuta K
    World J Oncol; 2019 Dec; 10(6):187-198. PubMed ID: 31921375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant.
    Zhao L; Cai X; Chen D; Ye X; Gao M; Lu L; Su H; Su M; Hou M; Xie C
    Radiat Oncol; 2019 Dec; 15(1):3. PubMed ID: 31892337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes and radiation pneumonitis after concurrent EGFR-tyrosine kinase inhibitors and radiotherapy for unresectable stage III non-small cell lung cancer.
    Xu K; Liang J; Zhang T; Zhou Z; Chen D; Feng Q; Xiao Z; Hui Z; Lu J; Wang X; Deng L; Liu W; Wang J; Zhai Y; Wang J; Bi N; Wang L
    Thorac Cancer; 2021 Mar; 12(6):814-823. PubMed ID: 33501781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer.
    Song J; Wang L; Ng NN; Zhao M; Shi J; Wu N; Li W; Liu Z; Yeom KW; Tian J
    JAMA Netw Open; 2020 Dec; 3(12):e2030442. PubMed ID: 33331920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.